These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37926852)

  • 1. Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis.
    Huang S; Zheng G; Yang K
    World J Surg Oncol; 2023 Nov; 21(1):349. PubMed ID: 37926852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
    Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
    JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
    Liu S; Gao W; Ning Y; Zou X; Zhang W; Zeng L; Liu J
    Front Immunol; 2022; 13():908173. PubMed ID: 35880172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of combination PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours: A systematic review.
    Yao Q; Gu L; Su R; Chen B; Cao H
    J Cell Mol Med; 2020 Nov; 24(22):13494-13506. PubMed ID: 33078904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
    Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
    JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
    Zhang M; Song J; Yang H; Jin F; Zheng A
    Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
    Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
    JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
    Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
    Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis.
    Shen X; Huang S; Xiao H; Zeng S; Liu J; Ran Z; Xiong B
    Eur J Hosp Pharm; 2023 Jan; 30(1):3-8. PubMed ID: 34497128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis.
    Mi Z; Zhang Y; Feng Z; Liu J; Wu J; Tan H; Ma X; Liu Z; Rong P
    Artif Cells Nanomed Biotechnol; 2022 Dec; 50(1):301-309. PubMed ID: 36217590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials.
    Guan J; Zhang J; Zhang X; Yuan Z; Cheng J; Chen B
    Medicine (Baltimore); 2022 Dec; 101(50):e32333. PubMed ID: 36550903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.
    Liu M; Cheng X; Ni R; Zheng B; Huang S; Yang J
    Front Immunol; 2022; 13():1006860. PubMed ID: 36189211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis.
    Liu X; Guo CY; Tou FF; Wen XM; Kuang YK; Zhu Q; Hu H
    Int J Cancer; 2020 Jul; 147(1):116-127. PubMed ID: 31633798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies.
    Luo H; Song G; Wang D; Li M; Dai N
    Front Immunol; 2022; 13():1059557. PubMed ID: 36544769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer.
    Guo L; Liang J; Dai W; Li J; Si Y; Ren W; Lu Y; Chen D
    Cancer Control; 2022; 29():10732748221107590. PubMed ID: 35673884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
    Li W; Jiang J; Huang L; Long F
    Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.